Defining NOTCH3 Target Genes in Ovarian Cancer
Xu Chen1, Michelle M. Thiaville1, Li Chen1,4, Alexander Stoeck1, Jianhua Xuan4, Min Gao1, Ie-Ming Shih1,2,3, and Tian-Li Wang2,3

Abstract

NOTCH3 gene amplification plays an important role in the progression of many ovarian and breast cancers, but the targets of NOTCH3 signaling are unclear. Here, we report the use of an integrated systems biology approach to identify direct target genes for NOTCH3. Transcriptome analysis showed that suppression of NOTCH signaling in ovarian and breast cancer cells led to downregulation of genes in pathways involved in cell-cycle regulation and nucleotide metabolism. Chromatin immunoprecipitation (ChIP)-on-chip analysis defined promoter target sequences, including a new CSL binding motif (N1) in addition to the canonical CSL binding motif, that were occupied by the NOTCH3/CSL transcription complex. Integration of transcriptome and ChIP-on-chip data showed that the ChIP target genes overlapped significantly with the NOTCH-regulated transcriptome in ovarian cancer cells. From the set of genes identified, we showed that the mitotic apparatus organizing protein DLGAP5 (HURP/DLG7) was a critical target. Both the N1 motif and the canonical CSL binding motif were essential to activate DLGAP5 transcription. DLGAP5 silencing in cancer cells suppressed tumorigenicity and inhibited cellular proliferation by arresting the cell cycle at the G2–M phase. In contrast, enforced expression of DLGAP5 partially counteracted the growth inhibitory effects of a pharmacologic or RNA interference–mediated NOTCH inhibition in cancer cells. Our findings define direct target genes of NOTCH3 and highlight the role of DLGAP5 in mediating the function of NOTCH3. Cancer Res; 72(9): 1-10. © 2012 AACR.

Introduction

NOTCH signaling has been shown to participate in cell fate determination and in progenitor cell maintenance during development. In mammals, there are 4 NOTCH receptors (NOTCH1–NOTCH4) that have distinct tissue expression patterns and are thought to function in specific cellular contexts. The NOTCH pathway is activated by receptor–ligand interactions on the cell membrane, which subsequently lead to a cascade of enzymatic cleavages of membrane NOTCH receptors by ADAM metalloprotease and γ-secretase complex. The cleaved product, intracellular fragment of NOTCH (NICD), translocates into the nucleus where it interacts with the nuclear DNA-binding factor, CSL (RBPjk), and recruits coactivators to turn on transcription of target genes. In addition to its role in the developmental processes, aberrant NOTCH signaling pathway was identified in a variety of human neoplastic diseases (1). For example, a tumor-promoting role of NOTCH1 has been reported in human T-cell acute lymphoblastic leukemia (T-ALL) because activating point mutations of NOTCH1 involving the extracellular heterodimerization domain and/or the C-terminal PEST domain of NOTCH1 are present in more than half of T-ALLs (2, 3). Amplification at the NOTCH3 genomic locus has been reported in ovarian high-grade serous carcinoma by us (4) and more recently by The Cancer Genome Atlas (5). Ovarian cancer cells with NOTCH3 gene amplification or overexpression are molecularly dependent on NOTCH signaling for cellular survival and growth (4), probably through a positive regulatory loop between NOTCH3 and its ligand, Jagged1 (6). In addition to ovarian cancer, NOTCH3 signaling aberrations have been implicated in other types of cancers. Translocation of the NOTCH3 gene occurred in a subset of non–small cell lung carcinoma (7) and constitutively expressed NOTCH3 induced neoplastic transformation in the breast, brain, and hematopoietic tissues (8–10). More recently, using an RNA interference approach, NOTCH3 but not NOTCH1, was found to be critical in maintaining cellular proliferation of ErbB2-negative breast cancers (11).

To better understand the molecular mechanisms by which NOTCH pathway activation contributes to cancer development, investigators have identified and characterized several downstream target genes that are directly regulated by the NOTCH pathway (12). However, most of the studies have focused on NOTCH1; NOTCH3-regulated genes have remained

Authors' Affiliations: Departments of 1Pathology, 2Oncology, and 3Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland; and 4Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, Virginia

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Current address for X. Chen: Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou, China.

Corresponding Author: Tian-Li Wang, Johns Hopkins Medical Institutions, 1550 Orleans Street, Room 306, Baltimore, MD 21231. Phone: 410-502-0863; Fax: 410-502-7943; E-mail: tlw@hmi.edum

doi: 10.1158/0008-5472.CAN-11-2181

©2012 American Association for Cancer Research.
largely unknown. To identify NOTCH3 direct target genes, we applied an integrated analysis of transcriptome and Chromatin immunoprecipitation (ChIP)-on-chip in ovarian cancer cells with NOTCH3 amplification and overexpression to screen for genes in which mRNA levels are regulated by NOTCH, and in which promoters are bound by the NICD3/CSL transcription complex.

Materials and Methods

**Affymetrix gene chip analysis**

Cell cultures were treated with 5 μmol/L MRK003 and were harvested at 24 and 48 hours. As a control, dimethyl sulfoxide was used in parallel under the same experimental conditions. Affymetrix GeneChip array, HG-U133 Plus 2.0, was used to analyze the transcriptome. The fold change of mRNA levels of each individual gene was calculated as the ratio of MRK003 treatment to control treatment at each time point. We used the logarithm of fold change as the data output (i.e., test statistic) which is defined as the probability of obtaining a test statistic at least as extreme as the one that is actually observed under the null hypothesis. For null distribution, we assumed that the test statistic followed a normal distribution in which the mean and SD were estimated from the control samples. We also implemented the Benjamini and Hochberg procedure (13) for multiple hypothesis testing and estimated the false discovery rate (FDR) for significantly expressed genes. Significantly upregulated and downregulated genes were determined by a predefined FDR cutoff (FDR ≤ 0.1) and P ≤ 0.003.

**ChIP analysis**

OVCAR3 cells were first treated with 5 μmol/L dimethyl dithiobispropionimidate (Thermo Scientific) followed by cross-linking with formaldehyde. Cells were lysed in a buffer containing 1% SDS, 10 mmol/L EDTA, and 50 mmol/L Tris-HCl, pH 8.0, and sonicated. Lysates were incubated with Protein G Sepharose (Invitrogen) for 1 hour. Bead cleared lysates were incubated with anti-NOTCH3 antibody (sc-5593: Santa Cruz or #3446; Cell Signaling) at 4°C overnight. After washes, the complexes were eluted by incubating beads in buffer containing 1% SDS and 0.1 mol/L NaHCO3 and incubated at 37°C for 30 minutes. Samples were treated with RNase A and subsequently proteinase K. DNA was proceeded for ChIP-quantitative PCR (qPCR) analysis as previously described (14). Threshold cycle numbers (Ct) were obtained using the iCycler Optical system interface software. Data were normalized with a standard curve, which was prepared from sonicated input (total) DNA. PCR primers are listed in Supplementary Table S4.

**ChIP-on-chip analysis**

The DNA sample from ChIP was amplified using a Sigma WGA2 Kit and purified using a QIAGEN QIAquick PCR Puriﬁcation Kit. For input DNA control, 200 ng of purified DNA was used for WGA2 PCR. An aliquot of each ampliﬁed sample was diluted to 5 ng/mL and used for qPCR testing with positive and negative control primers. In cases in which 4 μg of DNA was not produced from the WGA2 PCR, 10 ng of the WGA2 reaction was reampliﬁed using the WGA3 kit (Sigma) and retested with control primers. The NimbleGen 385K ReSeq promoter 1-plex array was used for sample hybridization. The NimbleGen program SignalMap was used to obtain signal peaks for each sample and to map these peaks to their corresponding genomic region. ChIP-on-chip data were analyzed by the Model-based analysis of 2-color arrays (MA2C) method (15), and the signal intensity (raw) data on each chip were normalized at probe level. A window-based peak detection approach was implemented on the normalized data to detect peak regions. A MA2C score was assigned with the median of the probes in the window and P value was calculated. A cutoff score of P = 0.005 was set for identifying signiﬁcant peaks. Finally, all signiﬁcant peak regions were mapped to the nearest genes.

**De novo motif discovery and enrichment analysis**

We carried out de novo motif discovery on the NOTCH3 ChIP-on-chip binding peak regions. For preprocessing, we ﬁrst used RepeatMasker to mask DNA sequences with interspersed repeats and low complexity. Then a Gibbs motif sampler algorithm in CisGenome was applied on the processed sequence data to extract top conserved motifs of 8 bp sequence length. To identify the most signiﬁcant motifs, we conducted enrichment analysis by comparing the occurrence frequency in ChIP-on-chip with occurrence in negative control regions, which were extracted from the human genome with matched physical properties of ChIP-on-chip binding sequences. We deﬁned the enrichment score as the ratio of these 2 occurrence rates, and the signiﬁcance of enrichment was determined based on the Fisher hypergeometric test.

**Gene set enrichment analysis**

We conducted gene set enrichment analysis for NOTCH3 ChIP target genes in transcriptome microarray data sets. Speciﬁcally, for each time point, we obtained the fold changes in gene expression and then calculated the test statistic, which was deﬁned as the summation of the absolute value of logarithm of fold changes of overlapped NOTCH3 ChIP-chip target genes in the up/downregulated transcriptome. To assess signiﬁcance of NOTCH3 ChIP-chip targets enriched in the NOTCH3 up/downregulated transcriptome, we carried out a signiﬁcance test and calculated the P value. We repeated 10,000 times to randomly sample the same number of genes from the entire up/downregulated gene population, and then calculated the test statistics to generate the null distribution. The empirical P value was calculated from the frequency by which the test statistic in the null distribution was larger than in the observed distribution.

**Electrophoretic mobility shift assay**

Electrophoretic mobility shift assay (EMSA) was conducted with a LightShift Chemiluminescent EMSA Kit (Pierce Biotechnology) according to the manufacturer’s protocol. Biotin-labeled oligonucleotide probes were manufactured by Sigma, and complimentary probes were annealed. The biotin-labeled, double-stranded probes were then incubated for 20 minutes at room temperature with nuclear lysates from HEK293T cells.
transfected with pcDNA-CSL-V5 or incubated with purified recombinant proteins (kind gifts from Dr. Stephen C. Blacklow, Harvard University). DNA/protein complexes were separated by electrophoresis, transferred to a nylon membrane, incubated with streptavidin-horseradish peroxide, and visualized by chemiluminescence.

Results

Genes and pathways that respond to NOTCH inactivation in ovarian and breast cancer cells

On the basis of gene expression microarray data set, we selected OVCAR3 and MCF7 as the cell models to identify NOTCH3-regulated genes because both cell lines express the highest level of NOTCH3 mRNA among all 4 NOTCH receptors (Fig. 1A; ref. 4). We chose to use a γ-secretase inhibitor, MRK003, to block NOTCH signals as MRK003 showed specific blocking of NICD generation. Using an antibody that recognizes various secretase cleavage products of NOTCH3 in Western blot analysis, we observed a noticeable decrease of the post-γ-secretase cleavage product, NICD3, and an increase of the pre-γ-secretase cleavage product, NEXT (Notch Extracellular Truncation) after MRK003 treatment (Fig. 1B). In contrast, MRK003 did not affect the levels either of full-length NOTCH3 or of the S1 cleavage product of NOTCH3, TM. The potency of MRK003 in suppressing γ-secretase was further confirmed in a Western blot analysis using an antibody specific to NICD1 (Fig. 1B).

Next, we conducted Affymetrix gene expression array analysis in OVCAR3 and MCF7 cells 24 and 48 hours after MRK003 treatment. Statistical analysis conducted in the transcriptome data set showed that in OVCAR3, 951 genes were significantly downregulated and 544 genes upregulated by MRK003 treatment in at least 1 of the 2 time points (P ≤ 0.003, FDR ≤ 0.1). In MCF7, 620 genes were downregulated and 950 genes upregulated (P ≤ 0.003, FDR ≤ 0.1). There was only a small fraction of genes shared by both cell lines, and the majority of NOTCH-regulated genes are specific to each cell line (Fig. 1C).

Ingenuity pathway analysis of the MRK003 downregulated genes carried out in each cell line showed that canonical pathways including purine and pyrimidine metabolism, cell-cycle regulation, and glycolysis/glucogenesis were enriched in both OVCAR3 and MCF7. Analysis of the MRK003 upregulated genes, on the other hand, identified pathways involved in generating nitric oxide and reactive oxygen species are common in both cell lines (Table 1). The list of differentially expressed genes following MRK003 treatment and their fold changes at both 24 and 48 hours have been deposited in https://share.johnshopkins.edu/twang16/OVCAR3_MCF7_MRK-003%20Genes?uniq=ieq61r.

Identification of NOTCH3 direct target genes by ChiP-on-chip

To identify genes that were directly regulated by NOTCH3, we applied a ChiP-on-chip assay in OVCAR3 cells using the 385K RefSeq promoter array, which contains 18,028 promoter regions for 24,659 transcripts (NimbleGen). Our results showed that a total of 797 promoters were enriched by ChiP-on-chip using an NICD3 antibody (P < 0.005; Supplementary Table S1). To validate the ChiP-on-chip results, we carried out qPCR in 10 randomly selected gene promoters. The ChiP-qPCR showed that binding of NICD3 to 8 of 10 representative promoter regions could be confirmed, among which is a previously reported NOTCH1 target gene, PN1 (Supplementary Fig. S1; ref. 15). To further validate the above result, we used a second anti-NOTCH3 antibody in the ChiP-qPCR analysis and
obtained results consistent with the first anti-NOTCH3 antibody (Supplementary Fig. S1).

De novo motif analysis of all 797 NICD3 ChIP-enriched promoter sequences revealed overrepresentation of the canonical CSL DNA-binding motif, TTCCCA (P = 0.016). However, the most significantly enriched sequence motif was GTTGCCAT (designated as N1), which has not been previously described (P < 0.0001; Fig. 2A). This new motif resembles the complementary sequence of the canonical CSL binding motif, albeit with several nucleotide substitutions (Fig. 2A). We assessed the distributions of ChIP-enriched DNA fragments including the canonical and the N1 motifs across the promoter regions (Fig. 2B). As compared with all ChIP-pull down DNAs (Fig. 2B, top), the binding sites of N1 and canonical motifs shared a very similar distribution—with more binding activity observed near the transcription initiation site (Fig. 2B, middle and bottom). We further analyzed the promoter sequences bound by NOTCH3. Among 601 promoter sequences that were available in the BioMart database, the N1 motif was present in approximately 90% of the NOTCH3 ChIP target genes. Furthermore, the majority (86%) of the NOTCH3-bound promoters contained paired CSL and N1 motifs (Supplementary Fig. S2A). The enrichment of the N1-CSL motif pair in the NOTCH3-bound promoters is significant as compared with their presence in the non-NOTCH3-bound promoters (P < 0.01, the Fisher exact test). The average distance between paired CSL and N1 motifs (defined as closest adjacent CSL and N1 motifs) was 238 base pairs; the distance distribution between paired CSL and N1 motifs is shown in Supplementary Fig. S2B.

We also compared the current NOTCH3 ChIP-on-chip data with a previous NOTCH1 ChIP-on-chip study that was carried out using a RefSeq promoter array (16). There was minimal overlap of the ChIP target genes between these 2 studies, with the exception of 1 gene, LGMN. However, we found that in addition to the canonical CSL binding motif, N1 motif was also significantly enriched in the NOTCH1-ChIP target promoters (Supplementary Fig. S3; ref. 16). The above results indicate that both NOTCH3/CSL and NOTCH1/CSL transcriptional complexes directly bound to the N1 motif or to the region in close proximity to the N1 motif.

To test whether these 797 NOTCH3-ChIP target genes were enriched in the NOTCH3-regulated transcriptome based on the MRK003 study, we conducted Gene Set Enrichment Analysis in both OVCAR3 and MCF7 transcriptome data sets. Our analysis showed that in the OVCAR3 cells, ChIP targets were significantly enriched in the NOTCH3 upregulated transcriptome 24 hours after MRK003 treatment and in downregulated transcriptome 48 hours after treatment (P < 0.05). In contrast, ChIP targets were not enriched in NOTCH-regulated transcriptome of MCF7 cells at either of the time points (Supplementary Table S2).

By integrating NOTCH3-ChIP targets with the NOTCH3-regulated transcriptome in OVCAR3 cells, we identified a total of 33 genes that overlapped in both data sets (Fig. 2C and

### Table 1. Canonical pathways in Notch-regulated transcriptome

<table>
<thead>
<tr>
<th>Ingenuity canonical pathways</th>
<th>MCF7</th>
<th>OVCAR3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P</td>
<td>Ratio</td>
</tr>
<tr>
<td>MRK-003 downregulated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell-cycle control of chromosomal replication</td>
<td>0.00</td>
<td>0.47</td>
</tr>
<tr>
<td>Pyrimidine metabolism</td>
<td>0.00</td>
<td>0.13</td>
</tr>
<tr>
<td>ATM signaling</td>
<td>0.00</td>
<td>0.19</td>
</tr>
<tr>
<td>Cyclins and cell-cycle regulation</td>
<td>0.00</td>
<td>0.13</td>
</tr>
<tr>
<td>Breast Cancer Regulation by Stathmin1</td>
<td>0.00</td>
<td>0.09</td>
</tr>
<tr>
<td>Cell cycle: G2-M DNA damage checkpoint regulation</td>
<td>0.00</td>
<td>0.17</td>
</tr>
<tr>
<td>Protein Ubiquitination Pathway</td>
<td>0.00</td>
<td>0.07</td>
</tr>
<tr>
<td>Purine metabolism</td>
<td>0.00</td>
<td>0.07</td>
</tr>
<tr>
<td>p53 Signaling</td>
<td>0.00</td>
<td>0.11</td>
</tr>
<tr>
<td>Germ cell-sertoli cell junction signaling</td>
<td>0.00</td>
<td>0.08</td>
</tr>
<tr>
<td>RAN signaling</td>
<td>0.01</td>
<td>0.17</td>
</tr>
<tr>
<td>Prostate cancer signaling</td>
<td>0.01</td>
<td>0.21</td>
</tr>
<tr>
<td>Molecular mechanisms of cancer</td>
<td>0.02</td>
<td>0.25</td>
</tr>
<tr>
<td>Glycolysis/glucogenesis</td>
<td>0.05</td>
<td>0.31</td>
</tr>
<tr>
<td>Antiproliferative role of TOB in T-cell signaling</td>
<td>0.05</td>
<td>0.34</td>
</tr>
<tr>
<td>MRK-003 upregulated</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biosynthesis of steroids</td>
<td>0.00</td>
<td>0.29</td>
</tr>
<tr>
<td>Glycine, serine and threonine metabolism</td>
<td>0.00</td>
<td>0.13</td>
</tr>
<tr>
<td>Production of nitric oxide and reactive oxygen species in macrophages</td>
<td>0.00</td>
<td>0.09</td>
</tr>
<tr>
<td>TR/RXR activation</td>
<td>0.02</td>
<td>0.13</td>
</tr>
<tr>
<td>Metabolism of xenobiotics by cytochrome P450</td>
<td>0.02</td>
<td>0.14</td>
</tr>
</tbody>
</table>

Chen et al.

Cancer Res; 72(9) May 1, 2012

Cancer Research

OF4 Cancer Res; 72(9) May 1, 2012 Cancer Research

Downloaded from cancerres.aacrjournals.org on April 15, 2017. © 2012 American Association for Cancer Research.
Supplementary Table S3). To test whether these genes were expressed in ovarian carcinoma tissues, we analyzed a previously published transcriptome dataset using Oncomine. In ovarian cancer, we found that NOTCH3 and 5 of its regulated genes, including EHF, DLGAP5, DNAJC19, NCOA5, and NRAS, were overexpressed in ovarian carcinoma tissue as compared with normal ovarian surface epitheliums (P < 0.05; Supplementary Fig. S4). We selected DLGAP5 (Disks large-associated protein 5, also known as HURP, hepatoma upregulated protein) for further characterization because its binding intensity in the ChIP assay was the highest among all ChIP target genes (Supplementary Table S3).

Binding of the NICD3/CSL transcription complex to the new N1 motif

The promoter region of DLGAP5 contains 3 canonical CSL binding motifs, which are located at −2354 bp (C1), −1862 (C2), and −496 (C3). The ATG translation initiation codon is located in exon 2; thus, it is of note that C3 is located in the intron between exons 1 and 2. The novel NICD3 binding motif (N1) as discovered in this study is located at intron between exons 1 and 2. The novel NICD3 binding motif contains 3 consecutive G or C nucleotides that are also present in the canonical CSL motif, it is possible that the N1 site was identiﬁed previously as a variant of the CSL binding motif. To test this hypothesis, we conducted EMSA assay by mixing recombinant protein with biotinylated N1 probe. A band shift in EMSA when the nuclear extract was prepared from HEK293T cells. This band shift was competitively abolished by unlabeled wild-type N1 probe but not by the mutant N1 probe (Fig. 3C).

To further confirm direct binding of the NICD3/CSL protein complex to the unique C3/N1 pair, we conducted EMSA assays. Wild-type biotinylated DNA probes encompassing the C3/N1 region were mixed with nuclear extract prepared from HEK293T cells, which contains abundant endogenous CSL and NOTCH3 proteins. A specific band shift was observed, a phenomenon that could be competitively blocked by unlabeled wild-type probes in a dose-dependent manner. This band shift was not blocked if the competing probe contained either C3 or N1 mutated sequences (Fig. 3B). These results indicate that both canonical and N1 motif sequences are required for the formation and/or stabilization of the NICD3/CSL/DNA complex. Next, we determined whether the NICD3/CSL protein complex interacted with the N1 motif alone. Using oligonucleotide probes that encompassed only the N1 motif, we detected a speciﬁc band shift in EMSA when the nuclear extract was prepared from HEK293T cells. This band shift was competitively abolished by unlabeled wild-type N1 probe but not by the mutant N1 probe (Fig. 3C).
replacing GGC from the N1 motif with CCC from the canonical CSL binding motif and used it in the EMSA competition assay (Fig. 4, top). The results showed that this new probe (N1 backbone but with CCC rather than GGC in the middle) could efficiently compete with the parental wild-type N1 probe (lane 4, Fig. 4), suggesting functional similarity between these 2 motifs.

To determine whether the NICD3 protein could complex with the N1 DNA probe and CSL protein, we carried out additional EMSA experiments, and showed a super shift when both NICD3 and CSL proteins were present as compared with the control groups with individual proteins (lane 7, Fig. 4). Next, we determined whether the N1 site could be bound by NOTCH1/CSL complex. As shown in lane 12 of Fig. 4, a similar super shift was detected in the presence of both NICD1 and CSL proteins. This band shift could also be competitively blocked by unlabeled wild-type N1 probe and unlabeled CSL probe, but not by the mutant N1 probe.

Figure 3. Binding of NOTCH3 transcription complex with the N1 motif. A, distribution of the 3 canonical CSL binding sites (C1–C3) and the new binding motif (N1) in the DLGAP5 promoter region (top). ChIP was carried out followed by qPCR using primers flanking C1, C2, and C3/N1 promoter regions (bottom). Immunoglobulin G (IgG) was used as the normalization control. B, the probes for the EMSA assay were generated from the C3/N1, mutant N1 (with wild-type C3), and mutant C3 (with wild-type N1) sequences. Nuclear extracts from HEK293T cells were mixed with biotin-labeled probes. An asterisk indicates the specific shifted band that can be competed away by excess unlabeled wild-type probes but not by either mutant N1 or mutant C3 probes. The mutated sequences are highlighted. C, nucleotide sequences containing only the N1 region were used for EMSA assay. A specific band shift (asterisk) can be competed away by increasing concentrations of unlabeled wild-type probes, but not by unlabeled N1 mutant probes.

N1 binding motif is essential for transcription of NOTCH3-regulated genes

To determine whether the C3/N1 promoter region was involved in transcriptional regulation of DLGAP5, we generated a luciferase DLGAP5 promoter reporter containing the C3/N1 paired motif sequences. A deletion mutant lacking both C3 and N1 binding motifs was used as a control (Fig. 5A). In addition, to determine the individual contributions of C3, N1, and their adjacent sequences to DLGAP5 transcription, we created a series of DLGAP5 promoter reporter constructs with different structural modifications including microdeletion at the C3 or N1 motif, and various truncations in the promoter region (Fig. 5A). The results showed that the wild-type reporter yielded a higher level of luciferase activity in cells ectopically expressing NICD3 than those without. In contrast, microdeletion in either the C3 or N1 sequence reduced promoter activity in the presence of
NICD3 to the level obtained without NICD3. Interestingly, microdeletion in both N1 and C3 sites did not lead to a further reduction in the reporter activity, suggesting that both C3 and N1 sequences are required for DLGAP5 promoter activity and may play an equivalent role in transcriptional regulation of DLGAP5. The 4 truncating deletion reporters all exhibited very low basal levels of reporter activity as compared with reporters with wild-type sequences or with C3/N1 microdeletions. Of note, Truc-2 showed that the presence of C3/N1 site alone was not sufficient to support the basal transcriptional activity of DLGAP5. The data from truncation mutants suggest that the C3/N1 sequences in the DLGAP5 promoter are required but not sufficient to confer full transcriptional activity of DLGAP5 (Fig. 5A).

The above ChIP-on-chip study also identified PINI (peptidyl-prolyl cis/trans isomerase-1) as a potential NOTCH3-regulated gene. PINI has been reported as a NOTCH1 direct target gene (17), but its transcriptional regulation by NOTCH3 has not been established. Analysis of the PINI promoter sequence showed that the N1 motif was present at 65 bp proximal to the previously reported canonical CSL binding site (Fig. 5B). Deletion mutants of either the CSL motif or the N1 motif in the PINI promoter were subsequently created, and the results showed that microdeletion of either the canonical CSL binding site or the N1 site led to a similar effect in reducing PINI transcriptional activity (Fig. 5B).

Next, we determined whether NOTCH3 protein was involved in regulating the transcriptional activity of DLGAP5. OVCAR3 cells were transfected with a DLGAP5 wild-type promoter reporter and were treated with either MRK003 or NOTCH3 shRNA to reduce the NICD3 protein level.

We found that either NOTCH3 shRNA or MRK003 treatment significantly suppressed DLGAP5 reporter activity (Supplementary Fig. S5A) and the protein levels of NOTCH3 and DLGAP5 were selectively decreased by NOTCH3 shRNAs (Supplementary Fig. S5B).

**DLGAP5 is a potential mediator of NOTCH3 signaling in cancer cells**

We next asked whether constitutive DLGAP5 expression could rescue the growth suppressive effect caused by inactivation of the NOTCH3 pathway, a phenotype that has been previously reported in other cancer types (4, 11). OVCAR3 and MCF7 cancer cells were transfected with a cytomegalovirus-driven expression vector to ectopically express DLGAP5 (Fig. 6A) and the cells were then treated with either MRK003 or NOTCH3 shRNAs to suppress NOTCH3 signaling. As compared with transfection with the vector only control, transfection with the DLGAP5 cDNA expressing construct resulted in significant protection from the antiproliferative effect of MRK003 or NOTCH3 shRNA (Fig. 6B). The above result suggests that DLGAP5 expression could reverse, at least in part, the antiproliferative effect of NOTCH3 pathway inactivation.

**Biological effects of DLGAP5 expression in cancer cells**

Next, we determined whether DLGAP5 expression was essential for cellular survival and growth of ovarian cancer cells. We have previously shown that ovarian cancer frequently harbors NOTCH3 amplification and overexpression, and more importantly, ovarian cancer cells are molecularly dependent on the NOTCH3 pathway activation for cellular proliferation and survival (4). OVCAR3, OVCAR5, and A2780 ovarian cancer cell lines were selected for this functional
analysis because they express high levels of DLGAP5 mRNA (Supplementary Fig. S6). The efficiency of 2 DLGAP5 shRNAs in reducing DLGAP5 transcript levels was shown by RT-qPCR (Supplementary Fig. S7). After gene knockdown using either DLGAP5 shRNA1 or shRNA3, the percentage of cells in the G2–M phase was significantly increased as compared with control shRNA-treated cells (Supplementary Fig. S8A). Cellular proliferation was significantly reduced in DLGAP5-shRNA–treated groups in all 3 ovarian cancer cell lines (Supplementary Fig. S8B). However, no evidence of increased apoptotic activity was observed in cells treated with DLGAP5 shRNAs (data not shown). In addition, DLGAP5 shRNA-treated OVCA5 and A2780 cells failed to form subcutaneous tumors in nude mice, whereas control cells treated with scrambled shRNA were highly tumorigenic (Supplementary Fig. S9).

**Discussion**

In this study, we found that pathways involved in nucleotide biosynthesis and cell-cycle checkpoint regulation are enriched in the NOTCH transcriptome of both OVCA3 and MCF7 cells; interestingly, these pathways were also affected by NOTCH signaling in NOTCH1-predominant T-ALLs (16, 18). However, further analysis shows that there is only small overlap in the NOTCH-regulated genes among OVCA3, MCF7, and T-ALLs (16). This finding indicates that although cell lines from different lineages can share common NOTCH-regulated pathways, the genes that are directly involved could be quite distinct. The fact that the NOTCH3 ChIP targets carried out in OVCAR3 were only overrepresentative in the NOTCH transcriptome of OVCAR3 cells but not in the transcriptome obtained from MCF7 further supports the view that direct target genes of NOTCH are highly context- and cell type-specific. It is plausible that unique cofactors present in distinct cell type play a significant role in dictating the DNA-binding specificity and/or affinity of the NOTCH transcription complex.

A new NICD3/CSL binding motif (N1) was identified in this study and promoter reporter analysis in DLGAP5 and PIN1 showed that the N1 motif likely plays an equally important role as the canonical CSL binding motif in transcriptional regulation. Because the majority of NOTCH3 target genes contain paired N1-CSL motifs at the promoter, it is plausible that N1 and canonical CSL motif sequences collaborate to facilitate the formation and/or stabilization of the DNA-binding complex...
of the NICD3/CSL transcription complex. In fact, we think the N1 motif may represent a degenerative version of the CSL binding site, as the N1 motif contains a core sequence of GCC that is very similar to the CCC that is found in the core of the canonical CSL binding motif. In addition, the sequences flanking the G-C core are either A or T bases, implying conservative nucleotide usage at these positions. Therefore, it is not surprising that the N1 motif is present in target sequences pulled down by both Notch3- and Notch1-ChIP. Our EMSA data further showed binding of the N1 motif sequence to NICD3/CSL and NICD1/CSL complexes, providing a plausible role of N1 motif in NOTCH1 and NOTCH3 transcriptional regulation.

Because the occurrence of the N1 motif is more frequent in the Notch3-ChIP target sequences than in the Notch1-ChIP target sequences (Supplementary Fig. S3), it is likely that the NICD3 transcription complex has a higher binding affinity to the N1 motif than does the NICD1 complex. However, this interpretation is tentative, because the differences may merely reflect the use of different anti-Notch antibodies. On the contrary, we have recently carried out ChIP-chip using antibodies reacting to other transcriptional factors or chromatin remodeling proteins including PBX1, RNA polymerase II, RSB-1, and SNF2H but did not identify the enrichment of N1 and canonical CSL motif sequences, indicating that NOTCH complexes specifically interact with both motifs. Further genomewide ChIP-chip or ChIP-seq study is required to address whether the upstream regulatory regions including enhancers of which the sequences were not covered by the arrays could also interact with NOTCH3.

We have also established direct transcriptional regulation of DLGAP5 by NOTCH3 in this study. DLGAP5 has been shown to be an essential component of the mitotic apparatus (19, 20), and its depletion could lead to prolonged prometaphase and aberrant chromatin segregation (21). In fact, DLGAP5 was implicated as an oncogenic target of Aurora A, a major mitotic serine/threonine kinase (22), and phosphorylation of DLGAP5 by Aurora A is prerequisite in regulating spindle assembly and function during mitosis (20). This study provides new evidence that DLGAP5 is required for the G2–M transition, and its expression is required for tumor growth in a mouse xenograft model. Therefore, the demonstration that DLGAP5 is a direct downstream target of NOTCH3 establishes a new molecular wiring that may, at least partially, explain how NOTCH3 activation contributes to ovarian cancer pathogenesis from the perspective of aberration of mitotic apparatus.

In conclusion, the integrated transcriptome and promoter occupation analysis has allowed us to discover a new NICD/CSL binding motif and to identify NOTCH3 direct target genes in ovarian cancer cells. These results could serve as a molecular foundation for future studies aimed at understanding the mechanisms of NOTCH3 signaling in tumorigenesis and may facilitate the design of NOTCH3-based cancer therapy.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
The authors thank Dr. Stephen C. Blacklow for critical reading of this manuscript and for gifts including purified CSL and NOTCH proteins, Dr. Giannino Del Sal for the PIN1 promoter reporter plasmid, and Dr. Masayuki Futagami for help in constructing the PIN1 promoter deletion mutants.

Grant Support
This work was supported by the Ovarian Cancer Research Fund (T.-L. Wang), American Cancer Society (T.-L. Wang), and NIH/NCI grants RO1CA148826 (T.-L. Wang), RO1CA129080 (L.-M. Shih), RO1CA103937 (L.-M. Shih), and U24CA160036 (L.-M. Shih).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 1, 2011; revised January 24, 2012; accepted February 21, 2012; published OnlineFirst March 6, 2012.
References


Defining NOTCH3 Target Genes in Ovarian Cancer

Xu Chen, Michelle M. Thiaville, Li Chen, et al.

Cancer Res  Published OnlineFirst March 6, 2012.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-2181

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/03/06/0008-5472.CAN-11-2181.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.